Novelix Pharmaceuticals Limited will issue and allot 12,00,000 equity shares to non-promoters on a preferential basis to raise ₹6.84 crore, subject to shareholder approval. The board decided on the issuance at a meeting held on June 4, 2026, setting the issue price at ₹57 per share, comprising a face value of ₹10 and a premium of ₹47. The capital raise aims to bolster the company's financial resources for growth and expansion.

The proposed allotment of 12,00,000 shares will be made to 18 specific investors identified as public shareholders. The issuance complies with Section 42 and 62 of the Companies Act, 2013, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Shareholder approval will be sought through an Extra Ordinary General Meeting (EGM), for which the company has fixed June 24, 2026, as the record date to determine eligibility.

Preferential Allotment Details

The breakdown of the proposed issuance to non-promoters is detailed below:

EGM and Voting Schedule

The EGM is scheduled for July 1, 2026, at 3:30 PM via video conferencing. Remote e-voting facilities will be available to eligible shareholders from June 28 at 9:00 am to June 30 at 5:00 pm. The intimation regarding the board meeting and the preferential issue was submitted to the exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Venkateswarlu Pulluru, Whole-time Director, signed the regulatory filing on June 5, 2026.

trimurthi has entered into an agreement with GMBU e.V., Halle (Saale), Germany, to facilitate the commercial scale-up of Astaxanthin production. This strategic move aims to transition the product from pilot scale to full commercial manufacturing at the company's research facilities in Hyderabad, India. The development is significant as it marks the progression of Novelix Pharmaceuticals Limited's capabilities in producing high-value nutraceutical ingredients.

The agreement was executed on June 2, 2026, under Regulation 30 of the listing regulations. Disclosures confirm that no special rights, such as the right to appoint directors or preferential share subscription, have been agreed upon between the parties. Furthermore, the transaction does not involve any shareholding in the counterparty entity and is not classified as a related party transaction.

The filing confirms that GMBU e.V. is not related to the promoter or promoter group of Novelix Pharmaceuticals Limited. The agreement was disclosed in compliance with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026. The company's registered office is located at H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Himayat Nagar, Hyderabad, Telangana- 500029.

Key Agreement Details